Toronto, Ontario (FSCwire) - Theralase Technologies Inc. (the
“Theralase” or “Company”) (TSXV: TLT) (OTCQX: TLTFF), a
clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds and
their associated drug formulations to safely and effectively destroy various cancers, is pleased to announce that it proposes to
conduct a non-brokered private placement offering of up to 5,000,000 units at a price of $0.20 per unit for gross proceeds of up
to $1 million. Each unit will consist of one common share of the Company and one common share purchase warrant with each
warrant entitling the holder to purchase one common share at an exercise price of $0.30 per share for a period of 24 months.
The Company intends to use the proceeds of the offering for the following:
- Advancement of Phase Ib Non-Muscle Invasive Bladder Cancer clinical study
- Advancement of Phase Ib New Oncology Indication clinical study
- Advancement of TLC-2500 therapeutic laser system
- Working capital and general corporate purposes
Subject to satisfaction of certain customary closing conditions, the offering is expected to close in one or more tranches on
or before May 16, 2016.
The securities offered have not been registered under the U.S. Securities Act of 1933, as amended, and may not be
offered or sold in the United States absent registration or an applicable exemption from the registration requirements.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of the
securities offered in any jurisdiction in which such offer, solicitation or sale would be unlawful.
About Theralase Technologies Inc.
Theralase is a clinical stage pharmaceutical company dedicated to the research and development of light activated
Photo Dynamic Compounds and their associated drug formulations to safely and effectively destroy various cancers. The Company in
its Cool Laser Division designs, manufactures and distributes patented and proprietary super-pulsed cool laser technology for the
treatment of knee pain, and in off-label use, the treatment of numerous nerve, muscle and joint conditions.
Additional information is available at www.theralase.com and www.sedar.com.
This news release contains "forward-looking statements" which reflect the current expectations
of management of the Company’s future growth, results of operations, performance and business prospects and opportunities. Such
statements include, but are not limited to, statements relating to: (i) Theralase’s ability to complete the offering on the
proposed terms or at all, and (ii) the timing of the proposed offering. Wherever possible, words such as "may",
"would", "could", “should”, "will",
"anticipate", "believe", "plan", "expect",
"intend", "estimate", "potential for" and similar expressions have been used
to identify these forward-looking statements. These statements reflect management's current beliefs with respect to future events
and are based on information currently available to management. Forward-looking statements involve significant risks,
uncertainties and assumptions. Many factors could cause the Company’s actual results, performance or
achievements to be materially different from any future results, performance or achievements that may be
expressed or implied by such forward-looking statements; including, without limitation, those listed in the filings made by the
Company with the Canadian securities regulatory authorities (which may be viewed at www.sedar.com). Should one or more of these risks or uncertainties materialize, or should assumptions
underlying the forward looking statements prove incorrect, actual results, performance or achievements may vary materially from
those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered
carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the
forward-looking statements contained in the news release are based upon what management currently believes to be reasonable
assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent
with these forward-looking statements. The Company disclaims any intention or obligation to revise forward-looking statements
whether as a result of new information, future developments or otherwise except as required by law. All forward-looking
statements are expressly qualified in their entirety by this cautionary statement.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of
the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For More Information:
Kristina Hachey, Chief Financial Officer
1.866.THE.LASE (843-5273)
416.699.LASE (5273)
info@theralase.com
www.theralase.com
To view the original release, please click here
Source: Theralase Technologies Inc. (TSX Venture:TLT, OTCQX:TLTFF, FWB:TTX)
To follow Theralase Technologies Inc. on your favorite social media platform or financial websites, please click on the icons
below.
Maximum News Dissemination by FSCwire. https://www.fscwire.com
Copyright © 2018 FSCwire